Inhoffenstraße 7
38124 Braunschweig
Niedersachsen
Deutschland
Telefon
+49 (531) 481170-0

YUMAB GmbH

YUMAB The success of next genera- tion antibody drug development relies on comprehensive discovery technolo- gies and strategies.

YUMAB bridges the gap between re- search innovation and novel therapies. Our advanced discovery platform provi- des access to challenging targets, enables new formats, and accelerates the deve- lopment of human antibodies at a high success rate.

From target discovery to fully characte- rised lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner.


Antibody Discovery

  • Advanced discovery platform for next generation biotherapeutics.
  • Access to challenging targets and new formats for drug discovery at high speed and success rate.
  • Fully integrated human antibody deve- lopment in one company – tailored to your needs.
  • Optimized discovery solution using antigen-positive cells as a target during selection.

Antibody Libraries

  • Universal human antibody libraries with more than 100 billion (1011) unique antibodies.
  • Highly productive pre-selected antibo- dy sequences.
  • Large epitope coverage and high hit rate.
  • Flexible business conditions.

Antibody Engineering

  • YUMAB® platform can be used for the engineering of externally generated already existing antibodies.
  • Two in-vitro evolution technologies.
  • Aktualisiert am

    26.07.2024
YUMAB GmbH 9. August 2024

YUMAB – pioneering antibody discovery since 2012

From target discovery to fully characterized lead – our experienced team leads biotech and pharma teams worldwide through the development process as your trusted, de-risking partner. Discover more in our corporate image video!